ArticleDigestive diseases and sciences2016
Adrenomedullin Therapy in Patients with Refractory Ulcerative Colitis: A Case Series.
Article in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial.Drug design, development and therapy · 2020Trial
- Adrenomedullin restores the human cortical interneurons migration defects induced by hypoxia.eLife · 2026Article
- Efficacy and safety of adrenomedullin for acute ischemic stroke (AMFIS): a phase 2, randomized, double-blinded, placebo-controlled, clinical trial.EClinicalMedicine · 2024Article
- Clinical Potential of Adrenomedullin Signaling in the Cardiovascular System.Circulation research · 2023Review
- Adrenomedullin alleviates mucosal injury in experimental colitis and increases claudin-4 expression in the colonic epithelium.FEBS open bio · 2023Article
- Review
- Adrenomedullin Therapy in Moderate to Severe COVID-19.Biomedicines · 2022Review
- Adrenomedullin: Not Just Another Gastrointestinal Peptide.Biomolecules · 2022Review
- Adrenomedullin: A Novel Therapeutic for the Treatment of Inflammatory Bowel Disease.Biomedicines · 2021Review
- Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.Journal of Crohn's & colitis · 2021Article
- Adrenomedullin: A vasoactive agent for sporadic and hereditary vascular cognitive impairment.Cerebral circulation - cognition and behavior · 2021Review
- Picomolar Affinity Antagonist and Sustained Signaling Agonist Peptide Ligands for the Adrenomedullin and Calcitonin Gene-Related Peptide Receptors.ACS pharmacology & translational science · 2020Article
- Identification of Small-Molecule Positive Modulators of Calcitonin-like Receptor-Based Receptors.ACS pharmacology & translational science · 2020Article
- Proceedings from the Albert Charitable Trust Inaugural Workshop on white matter and cognition in aging.GeroScience · 2020Review
- Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab.Internal medicine (Tokyo, Japan) · 2019Article
- Subcutaneously administered adrenomedullin exerts a potent therapeutic effect in a murine model of ulcerative colitis.Human cell · 2019Article
- Self-nanoemulsifying drug delivery system of bruceine D: a new approach for anti-ulcerative colitis.International journal of nanomedicine · 2018Article
- Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis.Frontiers in immunology · 2018Review
- Small molecules related to adrenomedullin reduce tumor burden in a mouse model of colitis-associated colon cancer.Scientific reports · 2017Article
- Lack of Adrenomedullin Results in Microbiota Changes and Aggravates Azoxymethane and Dextran Sulfate Sodium-Induced Colitis in Mice.Frontiers in physiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsAdrenomedullin (AM) is a multifunctional biologically active peptide that has an ameliorative effect against inflammatory bowel disease in several experimental models. We reported the first case where AM infusion dramatically improved symptoms and colonoscopy findings in patients with refractory ulcerative colitis (UC). To confirm the reproducibility of the efficacy and safety of AM infusion, this pilot study evaluated the clinical feasibility of intravenous administration of AM in patients with refractory UC.
methodsSeven patients with active refractory UC participated and received intravenous infusion of AM (1.5 pmol/kg/min) for 8 h daily for 14 days, and their Disease Activity Index (DAI) were evaluated before and 2 and 12 weeks after beginning AM administration.
resultsDAI were improved in all patients after AM administration. Within 2 weeks, marked declines in DAI (≥ 3 points and ≥ 30%) were observed in six patients (85.7%), while a more modest decline was observed in one patient (14.3%). Overall mean DAI improved from 9.3 ± 0.6 at baseline to 4.6 ± 0.8 at 2 weeks, and then to 1.2 ± 0.5 at 12 weeks. Endoscopic examination revealed substantial amelioration of ulcers, with mucosal healing and scarring. Four patients remained in clinical remission 12 months after AM treatment. AM administration produced significant increases in plasma AM concentrations (approximately 2.5-fold) that had a mild effect on blood pressure and heart rate, but with no serious adverse effects.
conclusionAM is a potentially useful agent that acts via a novel mechanism to safely induce mucosal healing and clinical remission in patients with refractory UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.